{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:39:09Z","timestamp":1792719549777,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth\u2019s penalized logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age of the 33 included patients was 54.6\u2009\u00b1\u200913.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25\/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). The median annual exacerbation rate decreased from 2 to 0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Mean FEV\u2081 increased from 1514 mL to 2188 mL (+\u2009674 mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and FEV\u2081 (% predicted) improved from 54.9% to 76.8% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Peripheral blood eosinophil counts decreased from a median of 720 cells\/\u00b5L to 0 cells\/\u00b5L (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27\u20130.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) and higher baseline FEV\u2081 (per 100 mL increase; OR 1.27, 95% CI 1.01\u20131.59;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037) were associated with clinical remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Benralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04518-2","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:55:49Z","timestamp":1785236149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3957","authenticated-orcid":false,"given":"Melis","family":"Ya\u011fd\u0131ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulu\u015f","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"4518_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 update. Available from: https:\/\/ginasthma.org."},{"issue":"2","key":"4518_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"10056","key":"4518_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327.","journal-title":"Lancet"},{"issue":"10056","key":"4518_CR4","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti\u2013interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"issue":"6","key":"4518_CR5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/all.15644","volume":"78","author":"GW Canonica","year":"2023","unstructured":"Canonica GW, Menzella F, Comberiati P, Paggiaro P, Heffler E, Braido F, et al. Clinical remission in severe asthma: a consensus definition. Allergy. 2023;78(6):1595\u2013609.","journal-title":"Allergy"},{"key":"4518_CR6","doi-asserted-by":"crossref","first-page":"106101","DOI":"10.1016\/j.rmed.2020.106101","volume":"171","author":"F Menzella","year":"2020","unstructured":"Menzella F, Fontana M, Galeone C, Castagnetti C, Ruggiero P, Facciolongo N. Clinical response to benralizumab in severe eosinophilic asthma: a real-life study. Respir Med. 2020;171:106101.","journal-title":"Respir Med"},{"issue":"10","key":"4518_CR7","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.3390\/jcm13103013","volume":"13","author":"L Pini","year":"2024","unstructured":"Pini L, Bagnasco D, Begh\u00e8 B, Braido F, Cameli P, Caminati M, et al. Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: a three-year real-life study. J Clin Med. 2024;13(10):3013.","journal-title":"J Clin Med"},{"issue":"4","key":"4518_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaip.2024.01.044","volume":"12","author":"WW Busse","year":"2024","unstructured":"Busse WW, Chupp G, Corbridge T, Stach-Klysh A, Oppenheimer J. Targeting asthma remission as the next therapeutic step toward improving disease control. J Allergy Clin Immunol Pract. 2024;12(4):894\u2013903.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1 Suppl","key":"4518_CR9","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaci.2025.05.033","volume":"156","author":"RK Katial","year":"2025","unstructured":"Katial RK, Wechsler ME, Akuthota P, Jackson DJ, Pavord I, Rogers L, et al. Consensus summary on the definition of asthma remission. J Allergy Clin Immunol. 2025;156(1 Suppl):S20\u20134.","journal-title":"J Allergy Clin Immunol"},{"issue":"1 Suppl","key":"4518_CR10","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jaci.2025.04.037","volume":"156","author":"DJ Jackson","year":"2025","unstructured":"Jackson DJ, Akuthota P, Lega Hoyte FC, Pavord I, Katial RK, Smolen J, et al. A critical look at the lexicon, parameters, and limitations of asthma remission definitions. J Allergy Clin Immunol. 2025;156(1 Suppl):S7\u201314.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4518_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.anai.2024.09.021","volume":"134","author":"WW Busse","year":"2025","unstructured":"Busse WW. The role of biologics in inducing remission in asthma. Ann Allergy Asthma Immunol. 2025;134(1):19\u201330.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1 Suppl","key":"4518_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","volume":"156","author":"I Pavord","year":"2025","unstructured":"Pavord I, Katial RK, Jackson DJ, Rogers L, Lega Hoyte FC, Smolen J, et al. Current data on biologics: Evaluating clinical remission in asthma. J Allergy Clin Immunol. 2025;156(1 Suppl):S15\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4518_CR13","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3390\/ijms24032455","volume":"24","author":"A Maglio","year":"2023","unstructured":"Maglio A, Vitale C, Pelaia C, D\u2019Amato M, Ciampo L, Sferra E, et al. Severe asthma remissions induced by biologics targeting IL5\/IL5R: results from a multicenter real-life study. Int J Mol Sci. 2023;24(3):2455.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4518_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","volume":"134","author":"S Mailhot-Larouche","year":"2025","unstructured":"Mailhot-Larouche S, Celis-Preciado C, Heaney LG, Couillard S. Identifying super-responders: A review of the road to asthma remission. Ann Allergy Asthma Immunol. 2025;134(1):31\u201345.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"4518_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/all.70031","volume":"81","author":"A Rattu","year":"2026","unstructured":"Rattu A, Dixey P, Charles D, Brightling C, Chung KF, Bossios A, et al. Predictors of response to biologics for severe asthma: A systematic review and meta-analysis. Allergy. 2026;81(1):24\u201355.","journal-title":"Allergy"},{"issue":"8","key":"4518_CR16","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jaip.2025.05.002","volume":"13","author":"I Farinha","year":"2025","unstructured":"Farinha I, Gibson PG, McDonald VM, Heaney LG. Treatable traits as a pathway to remission in asthma. J Allergy Clin Immunol Pract. 2025;13(8):1542\u201352.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4518_CR17","doi-asserted-by":"crossref","first-page":"106491","DOI":"10.1016\/j.rmed.2021.106491","volume":"185","author":"C Pelaia","year":"2021","unstructured":"Pelaia C, Busceti MT, Vatrella A, Rago GF, Crimi C, Terracciano R, et al. Real-life effectiveness of benralizumab in severe eosinophilic asthma: the ANANKE study. Respir Med. 2021;185:106491.","journal-title":"Respir Med"},{"issue":"2","key":"4518_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","volume":"159","author":"JE Kavanagh","year":"2021","unstructured":"Kavanagh JE, Hearn AP, Jackson DJ, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496\u2013506.","journal-title":"Chest"},{"key":"4518_CR19","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.2147\/JAA.S391807","volume":"15","author":"T Numata","year":"2022","unstructured":"Numata T, Araya J, Okuda K, Miyagawa H, Minagawa S, Ishikawa T, et al. Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study. J Asthma Allergy. 2022;15:1731\u201341.","journal-title":"J Asthma Allergy"},{"issue":"25","key":"4518_CR20","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"key":"4518_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/JAA.S567136","volume":"19","author":"M Vergles","year":"2026","unstructured":"Vergles M, Salai G, Tudori\u0107 N, Kova\u010devi\u0107 I, Kifer D, Lali\u0107 K, et al. Feasibility of a 50% dosing interval extension of anti\u2013IL-5 biologics in patients with severe asthma in clinical remission: A real-world validation study. J Asthma Allergy. 2026;19:567\u201381.","journal-title":"J Asthma Allergy"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04518-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04518-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:22:45Z","timestamp":1792718565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04518-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4518"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04518-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Scientific Research Ethics Committee of University of Health Sciences Ankara Atat\u00fcrk Sanatorium Training and Research Hospital (Approval No: 2024-B\u00c7EK\/509; March 25, 2026). Due to the retrospective nature of the study, the requirement for informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"493"}}